Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Under a co-development deal, Micromet (Munich, Germany) granted MedImmune (MEDI) North American development rights to its MT103 bispecific T cell
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury